A Michael Lincoff
Overview
Explore the profile of A Michael Lincoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
319
Citations
10290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kushner R, Ryan D, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al.
Obesity (Silver Spring)
. 2025 Feb;
33(3):452-462.
PMID: 39948761
Objective: The objective of this study was to assess safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo, beyond reduction in major adverse cardiovascular events, in patients with established cardiovascular...
2.
Laufs U, Lincoff A, Nicholls S, Li N, Bloedon L, Sasiela W, et al.
J Clin Lipidol
. 2025 Feb;
PMID: 39939212
Background: Cholesterol Lowering via bEmpedoic Acid Regimen (CLEAR) outcomes, a randomized, double-blind, placebo-controlled cardiovascular outcomes trial, and the largest prospective database of patients with statin intolerance (SI), demonstrated that bempedoic...
3.
Bays H, Bloedon L, Brennan D, Lei L, Lincoff A, Nicholls S, et al.
J Am Heart Assoc
. 2025 Feb;
14(4):e037898.
PMID: 39921511
Background: Obesity and hypercholesterolemia independently increase cardiovascular disease risk. This analysis evaluated the efficacy and safety of bempedoic acid in people with obesity participating in the CLEAR (Cholesterol Lowering via...
4.
Pencina K, Lincoff A, Klein E, Nissen S, Shang Y, Khan N, et al.
J Endocr Soc
. 2025 Feb;
9(3):bvaf002.
PMID: 39911523
Context: Whether circulating testosterone, dihydrotestosterone, and estradiol levels or testosterone replacement therapy (TRT) affects the risk of COVID-19 and whether COVID-19 affects response to TRT remains unknown. Objective: The study...
5.
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
McEwan P, Bog M, Faurby M, Foos V, Lingvay I, Lubker C, et al.
J Med Econ
. 2025 Jan;
28(1):268-278.
PMID: 39882599
Aims: The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV...
6.
Verma S, Emerson S, Plutzky J, Kahn S, Stensen S, Weeke P, et al.
J Am Coll Cardiol
. 2024 Nov;
85(5):541-545.
PMID: 39566870
No abstract available.
7.
Gibson C, Chi G, Duffy D, Bahit M, White H, Korjian S, et al.
J Am Coll Cardiol
. 2024 Sep;
84(22):2185-2192.
PMID: 39230545
Background: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances...
8.
Kosiborod M, Deanfield J, Pratley R, Borlaug B, Butler J, Davies M, et al.
Lancet
. 2024 Sep;
404(10456):949-961.
PMID: 39222642
Background: Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated with a high risk...
9.
Gibson C, Duffy D, Bahit M, Chi G, White H, Korjian S, et al.
Eur Heart J
. 2024 Sep;
45(47):5023-5038.
PMID: 39221651
Background And Aims: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary...
10.
Verma S, Colhoun H, Dicker D, Hovingh G, Kahn S, Kautzky-Willer A, et al.
J Am Coll Cardiol
. 2024 Sep;
84(17):1678-1682.
PMID: 39217575
No abstract available.